<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>04260741121013</udiDi>
    <basicUdiDi>426074112NVG00129</basicUdiDi>
    <tradeName>NovaTears</tradeName>
    <deviceName>Non-active ophthalmologic devices based on perfluorohexyloctane</deviceName>
    <manufacturerName>Novaliq GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000009618</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030299</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, LIQUID FLUIDS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>0500100001</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T20:08:43.677Z</lastUpdated>
  </row>
  <row>
    <udiDi>04260741123017</udiDi>
    <basicUdiDi>426074112NVG00129</basicUdiDi>
    <tradeName>NovaTears+Omega-3</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Novaliq GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000009618</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030299</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, LIQUID FLUIDS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>0500300001</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-18T02:10:11.916Z</lastUpdated>
  </row>
</eudamedExport>